Recon: FDA approves Merck’s Keytruda for advanced endometrial cancer; Pfizer recalls some BP drug lots due to nitrosamine impurity

• FDA Approves Merck’s Keytruda for Endometrial Carcinoma (Bloomberg) (Fierce) (Biospace)
• US FDA Oncology Center Makes Dose Optimization Personal (The Pink Sheet)
• Pfizer Recalls 6 Lots of Accuretic Tablets, 1 Lot of Quinapril (Bloomberg)
• Pfizer inks deal with UNICEF to supply Covid pill to poor countries, but advocates say it isn’t enough (STAT) (Bloomberg)
• White House officials say US has exhausted funds to buy potential fourth vaccine dose for all Americans (Washington Post)
• Official US Long Covid-19 Data Two Years Away, Hurts Research (Bloomberg)

• Lilly, Novartis join drugmakers in scaling back operations in Russia (Reuters) (Endpoints)
• Janssen’s BCMA-Targeting CAR-T, AstraZeneca’s Evusheld Among EU Verdict Hopefuls (The Pink Sheet)
• WHO On Dire Need For Essential Medicines In Ukraine (The Pink Sheet)
• Glaxo Sells $8.75 Billion of Bonds for Consumer Spinoff (Bloomberg)
• ‘Rising and sustained’ commercial investment in advanced therapy trials in UK (BioPharma Reporter)
• Younger Females' Cancer Incidence Increases Significantly In China (Scrip)
• Wockhardt, Serum Institute of India to build UK fill-finish plant in Wales (Endpoints)

• Omicron sub-variant BA.2 makes up about 35% of COVID variants in U.S., CDC says (Reuters)
• India considers opening COVID boosters to all adults, sources say (Reuters)

• Cadila's sterile injectable site in India hit with a Form 483 following a rare international inspection for FDA (Endpoints)
• Former Takeda vaccine chief to lead new COVID antiviral venture Aerium (Reuters)
• Takeda’s Natpara relaunch bid falls flat as manufacturing concerns drag on (Fierce)
• ‘Harmful and wasteful’: Many pediatric clinical trials end early and don’t report results (STAT)
• Pfizer, Abbott Labs, AbbVie Legal Chiefs Get Big Pharma Paydays (Bloomberg)
• With midphase data in hand, MediPrint lands investment to take drug delivery contact lens deeper into the clinic (Fierce)
• Lonza inks deal with first customer at recently-expanded China manufacturing site (Endpoints)
• Al Sandrock, former top scientist at Biogen, named CEO at Voyager Therapeutics (STAT)
• A new cell therapy startup from an immunotherapy pioneer raises $175M in KRAS quest (Endpoints)

• Dexcom's hospital glucose monitor leads latest FDA breakthrough designations (MedTech Dive)
• FDA labels Philips 2018 field correction for ventilators a Class I recall (MedTech Dive)
• Essure: Out Of Sight, But Not Out Of Mind For Many Women (MedTech Insight)
• Minute Insight: Pear Therapeutics Inks Agreement With SoftBank To Develop Japan-Focused Digital Therapeutic (MedTech Insight)

• Amgen, Pfizer’s Hospira Settle Neulasta Cancer Drug Patent Suit (Bloomberg)
• Merck Wins Appeal Over Bid to Arbitrate Vaccine Antitrust Case (Bloomberg)
• Teva and Allergan reach $107 million deal with Rhode Island over opioid crisis (STAT) (Law360)
• Seattle-based Covid-19 vaccine developer seeks $950M from Indian partner over trade secret theft (Endpoints)
• Sona Nanotech Defeats Investors’ Covid Saliva Test Failures Suit (Bloomberg)
• US appeals court rules in favor of Nevro in patent dispute with Boston Scientific (MedTech Dive)